Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Infectious Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
2030
2031
89bioPegozafermin
Clinical Trials (1)
Total enrollment: 762 patients across 1 trials
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Start: May 2024Est. completion: Aug 2031762 patients
Phase 3Recruiting
Related Jobs in Infectious Diseases
Director, Program Management
Metaphore Biotechnologies
Somerville, MA USA
9h ago
$179K - $237K/yr
Executive Director, Global Medical Expert HIV Prevention - GMA Virology & Inflammation
Gilead Sciences
United States - Field
22h ago
$317K - $411K/yr
Sr. Engineer, Process Systems (Contract)
VaxCyte
Visp, Valais, Switzerland
Yesterday
Contract Senior Research Associate, Protein Science
Keros Therapeutics
Lexington, Massachusetts, United States
Yesterday
Director, Health Economics & Outcomes Research (HEOR)
VaxCyte
San Carlos, California, United States
Yesterday
$242K - $282K/yr
Senior Manager, Contract Account Performance Specialist, Contract Strategy
Pfizer
Remote
Yesterday
$124K - $207K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 762 patients
1 companies competing in this space